# US 2026/0248746 A1 · Methods, compositions, and devices for drug or live cell microarrays

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0248746 A1
- Document ID: US20260248746A1
- Status: Published application
- Kind: A1
- Application number: 19/648,464
- Filed: 2026-04-15
- Published: 2026-08-27
- Earliest claimed: 2013-03-14
- Assignees: Pathak Holdings LLC
- Applicants: Pathak Holdings LLC
- Inventors: Chandrashekhar P. Pathak
- Web page: https://patentgrep.com/patent/US20260248746A1

## CPC

- A61K 31/155: Amidines ([IMAGE cpc-sch-A61K-1029.gif]), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 9/0021: {Intradermal administration, e.g. through microneedle arrays or needleless injectors}
- A61K 9/0024: {Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue (compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L)}
- A61K 9/0048: {Eye, e.g. artificial tears}
- A61K 9/0051: {Ocular inserts or implants}
- A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}
- A61K 9/1641: {obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers}
- A61K 9/1647: {Polyesters, e.g. poly(lactide-co-glycolide)}
- A61K 9/1658: {Proteins, e.g. albumin, gelatin}
- A61K 9/5031: {obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)}
- A61K 9/5052: {Proteins, e.g. albumin}
- A61K 31/337: having four-membered rings, e.g. taxol
- A61K 31/37: Coumarins, e.g. psoralen
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 31/573: substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A61K 31/7036: having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
- A61K 31/727: Heparin; Heparan
- A61K 41/0028: {Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation, e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds}
- A61K 47/02: Inorganic compounds
- A61K 47/32: Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers {, poly(meth)acrylates, or polyvinyl pyrrolidone}
- A61K 47/34: Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers (A61K47/10 takes precedence)
- A61L 27/225: {Fibrin; Fibrinogen}
- A61L 27/3804: {characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells}
- A61L 27/50: Materials characterised by their function or physical properties {, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials}
- A61M 5/3298: {Needles arranged in parallel}
- A61M 37/0015: {by using microneedles}
- A61M 37/0076: {Tattooing apparatus (apparatus for marking animals A01K11/00; vaccine applicators having needles or other puncturing means A61B17/205)}
- A61L 27/54: Biologically active materials, e.g. therapeutic substances {(A61L27/227 takes precedence)}
- A61L 2300/442: Colorants, dyes
- A61L 2400/06: Flowable or injectable implant compositions
- A61M 5/3015: {for injecting a dose of particles in form of powdered drug, e.g. mounted on a rupturable membrane and accelerated by a gaseous shock wave or supersonic gas flow (cell injection devices C12M3/006)}
- A61M 2037/0023: {Drug applicators using microneedles}
- A61M 2037/003: {having a lumen}
- A61M 2037/0046: {Solid microneedles}
- A61M 2037/0053: {Methods for producing microneedles}
- A61M 2205/36: related to heating or cooling
- A61M 2205/3606: cooled
- A61M 2205/3633: thermally insulated
- A61M 2205/3653: by Joule effect, i.e. electric resistance
- A61M 2207/00: Methods of manufacture, assembly or production
- C12Y 304/21068: Tissue plasminogen activator (3.4.21.68), i.e. tPA
- C12Y 304/24069: Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}
- C12Y: ENZYMES

## Abstract

This invention discloses methods and composition to form biodegradable polymer implant arrays in the live tissue. Artificial cavities are created in the live tissue by using laser ablation, oscillating needle, microneedle array and other methods. The cavities are then filled with biodegradable polymer solution. The solvent in the polymer solution is dissipated in the tissue to form a biodegradable polymer implant in artificial cavities. The cavities and implants formed are arranged to form of an array of implants. The biodegradable polymer in the cavity can also be loaded with drug to form biodegradable drug delivery array in the live tissue.

## Claims

### Claim 1

An implantable microneedle array, comprising:
a plurality of microneedles arranged in an array, each microneedle comprising:
a biodegradable crosslinked body having a tip and a base surface opposite the tip, the biodegradable crosslinked body comprising a three-dimensional polymer network formed by crosslinking reaction between electrophilic functional groups of a first biodegradable precursor and nucleophilic functional groups of a second biodegradable precursor, wherein the first and second biodegradable precursors together provide at least five reactive groups available for the crosslinking reaction, and wherein the crosslinking reaction occurs without free radical polymerization; and
a backing member coupled to the base surface of the microneedles.

### Claim 2 (depends on 1)

The implantable microneedle array of claim 1, wherein the array comprises at least four microneedles.

### Claim 3 (depends on 1)

The implantable microneedle array of claim 1, wherein the crosslinked body comprises a non-biodegradable polymeric core linked through a degradable ester group to segments that participate in the electrophilic and nucleophilic crosslinking reaction.

### Claim 4 (depends on 3)

The implantable microneedle array of claim 3, wherein the degradable ester group is selected from glutarate, succinate, adipate, suberate, polylactide, polycaprolactone, polyglycolate, polytrimethylene carbonate, or combinations thereof.

### Claim 5 (depends on 3)

The implantable microneedle array of claim 3, wherein the non-biodegradable polymeric core comprises polyethylene glycol or polyethylene oxide.

### Claim 6 (depends on 1)

The implantable microneedle array of claim 1, wherein:
the electrophilic groups are selected from maleimide, vinyl sulfone, acrylate, methacrylate, epoxide, isocyanate, aldehyde, NHS-ester, or combinations thereof, and
the nucleophilic groups are selected from thiol, amine, hydroxyl, or combinations thereof.

### Claim 7 (depends on 1)

The implantable microneedle array of claim 1, wherein the backing member comprises nylon, cotton, woven textile, metal, or ceramic.

### Claim 8 (depends on 1)

The implantable microneedle array of claim 1, wherein the crosslinked body further comprises a filler material.

### Claim 9 (depends on 8)

The implantable microneedle array of claim 8, wherein the filler material is water soluble and has a solubility greater than 1 gram per 100 grams of solvent.

### Claim 10 (depends on 8)

The implantable microneedle array of claim 8, wherein the filler includes biodegradable microspheres, sugars, salts, polymers, or combinations thereof.

### Claim 11 (depends on 1)

The implantable microneedle array of claim 1, wherein each microneedle has at least one of:
a cross-dimension from 1 micron to 3,500 microns;
a height from 5 microns to 5,000 microns;
a spacing from 1 micron to 10,000 microns;
a volume from 1×10−12 mL to 0.05 mL; or
a total number from 4 to 6,000 microneedles.

### Claim 12 (depends on 1)

The implantable microneedle array of claim 1, wherein the backing member is the same material as or a different material from the crosslinked body.

### Claim 13 (depends on 1)

The implantable microneedle array of claim 1, further comprising a visualization agent in the crosslinked body.

### Claim 14 (depends on 1)

The implantable microneedle array of claim 1, further comprising a therapeutic agent in the crosslinked body.

### Claim 15 (depends on 10)

The implantable microneedle array of claim 10, wherein the filler varies from 5% to 500% relative to weight of the precursors.

### Claim 16 (depends on 10)

The implantable microneedle array of claim 10, wherein the filler includes sodium iodide, sodium bicarbonate, citric acid or its salts, succinic acid or its salts, glutamic acid or its salts, magnesium chloride, calcium sulphate, calcium carbonate, maltose, galactose, sucrose, mannitol, trehalose, dextrin, xylitol, hyaluronic acid or derivatives thereof, dextran, polyvinyl pyrrolidone, polyvinyl alcohol, celluloses, cellulose derivatives, carboxymethyl cellulose, carboxymethylpropyl cellulose, cellulose sulphate, gelatin, collagen, fibrinogen, or combinations thereof.

### Claim 17 (depends on 10)

The implantable microneedle array of claim 10, wherein the filler includes a synthetic biodegradable polymer.

### Claim 18 (depends on 17)

The implantable microneedle array of claim 17, wherein the synthetic polymer includes PLGA, PLA, PGA, PCL, PTMC, polydioxanone, PEG-copolymers, poly(glycerol sebacate), polycarbonates, polyarylates, or combinations thereof.

### Claim 19 (depends on 1)

The implantable microneedle array of claim 1, wherein the crosslinked body degrades by hydrolysis or enzymatic degradation.

### Claim 20

A method of forming a microneedle array, comprising:
providing a mold having cavities shaped as microneedles arranged in an array;
combining a first biodegradable precursor having electrophilic groups with a second biodegradable precursor having nucleophilic groups;
introducing the combined precursors into the cavities;
crosslinking the electrophilic and nucleophilic groups within the mold to form a biodegradable microneedle body without free radical polymerization;
attaching a backing member to the microneedle body; and
removing the microneedle array from the mold.

### Claim 21 (depends on 20)

The method of claim 20, wherein the first biodegradable precursor comprises a polyethylene glycol core linked through a degradable ester group to terminal electrophilic groups, and the second biodegradable precursor comprises a polyethylene glycol core linked through a degradable ester group to terminal nucleophilic groups.

### Claim 22 (depends on 20)

The method of claim 20, wherein the electrophilic groups are NHS-ester groups and the nucleophilic groups are amine groups, and the reacting step forms amide bonds between the first and second precursors.

### Claim 23 (depends on 20)

The method of claim 20, wherein the reacting step is performed at a pH between 6.0 and 7.8 and at a temperature between 20° C. and 40° C.

### Claim 24 (depends on 20)

The method of claim 20, further comprising adding a filler material to the cavities prior to or during the introducing step, wherein the filler material is selected from biodegradable microspheres, sugars, inorganic salts, water-soluble polymers, or combinations thereof.

### Claim 25 (depends on 20)

The method of claim 20, further comprising incorporating a therapeutic agent into the cavities prior to or during the introducing step such that the therapeutic agent is entrapped within the crosslinked biodegradable microneedle body upon completion of the reacting step.

### Claim 26 (depends on 20)

The method of claim 20, wherein the mold is a silicone rubber mold and the cavities have a pyramidal, conical, or cylindrical shape.

### Claim 27 (depends on 20)

The method of claim 20, further comprising drying or lyophilizing the crosslinked biodegradable microneedle body prior to withdrawing the microneedles from the mold.

### Claim 28 (depends on 20)

The method of claim 20, wherein the backing member is attached to base surfaces of the microneedles by applying a pressure-sensitive adhesive tape to the base surfaces prior to withdrawing the microneedles from the mold.

### Claim 29 (depends on 20)

The method of claim 20, wherein the first and second precursors together provide at least five reactive groups available for crosslinking, and each precursor individually provides at least two reactive groups.

### Claim 30 (depends on 20)

The method of claim 20, wherein the degradable ester group linking the polyethylene glycol core to the electrophilic or nucleophilic terminal groups is selected from glutarate, succinate, adipate, suberate, or combinations thereof, such that the crosslinked biodegradable microneedle body undergoes hydrolytic degradation in vivo by cleavage of the ester linkage.
